Eli Lilly’s Zepbound tops Wegovy in head-to-head weight reduction trial
Eli Lilly mentioned on Wednesday sufferers taking its weight problems drug Zepbound misplaced 47% extra weight than those that got Novo Nordisk’s Wegovy within the first giant, head-to-head trial of the extremely in-demand rival medicines. Within the 751-person trial, Zepbound helped sufferers lose a mean of 20% of their weight after 72 weeks in comparison
Read More